• 550 Citations
  • 11 Scopus h-Index
19982019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Steven Attia is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 2 Similar Profiles
Sarcoma Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Hemangiosarcoma Medicine & Life Sciences
Follicular Dendritic Cell Sarcoma Medicine & Life Sciences
Doxorubicin Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1998 2019

  • 550 Citations
  • 11 Scopus h-Index
  • 37 Article
  • 1 Review article

A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas

Jones, R. L., Chawla, S. P., Attia, S., Schöffski, P., Gelderblom, H., Chmielowski, B., Le Cesne, A., Van Tine, B. A., Trent, J. C., Patel, S., Wagner, A. J., Chugh, R., Heyburn, J. W., Weil, S. C., Wang, W., Viele, K. & Maki, R. G., Jan 1 2019, In : Cancer.

Research output: Contribution to journalArticle

Open Access
docetaxel
gemcitabine
Sarcoma
Confidence Intervals
Safety
1 Citation (Scopus)

Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma

Davis, L. E., Bolejack, V., Ryan, C. W., Ganjoo, K. N., Loggers, E. T., Chawla, S., Agulnik, M., Livingston, M. B., Reed, D., Keedy, V., Rushing, D., Okuno, S. H., Reinke, D. K., Riedel, R. F., Attia, S., Mascarenhas, L. & Maki, R. G., Jun 1 2019, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37, 16, p. 1424-1431 8 p.

Research output: Contribution to journalArticle

Osteosarcoma
Disease-Free Survival
Placebos
Sarcoma
Clinical Trials Data Monitoring Committees

Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial

Younger, E., Ballman, K., Lu, Y., Pápai, Z., Van Tine, B. A., Attia, S., Schöffski, P., Reinke, D., Tap, W. D. & Jones, R. L., Jan 1 2019, In : Journal of Geriatric Oncology.

Research output: Contribution to journalArticle

Open Access
Doxorubicin
Anthracyclines
Sarcoma
TH 302
Drug Therapy
3 Citations (Scopus)

Association between programmed death-Ligand 1 expression and the vascular endothelial growth factor pathway in angiosarcoma

Bagaria, S. P., Gatalica, Z., Maney, T., Serie, D., Parasramka, M., Attia, S., Krishna, M. & Joseph, R. W., Mar 22 2018, In : Frontiers in Oncology. 8, MAR, 71.

Research output: Contribution to journalArticle

Hemangiosarcoma
Vascular Endothelial Growth Factor A
Ligands
Neoplasms
Gene Expression
1 Citation (Scopus)

Growing Role of Regorafenib in the Treatment of Patients with Sarcoma

Agulnik, M. & Attia, S., Jun 21 2018, (Accepted/In press) In : Targeted Oncology. p. 1-6 6 p.

Research output: Contribution to journalArticle

Sarcoma
Gastrointestinal Stromal Tumors
Leiomyosarcoma
Therapeutics
Synovial Sarcoma